Cancer test kit GENESEEQPRIME™HRD

oncologyfor precision medicineSNV

GeneseeqPrime™HRD is a next-generation sequencing-based laboratory developed test that analyzes homologous recombination deficiency (HRD)-related genomic instabilities through a genome-wide analysis approach. It also detects genomic alterations in 437 cancer-relevant genes, including BRCA1/2 and other homologous recombination repair (HRR)-relevant genes. WHO IS IT FOR Patients with solid tumors seeking precision medicine, including PARP inhibitor selection, other targeted therapy options and immunotherapies SAMPLE TYPE Tumor tissue (FFPE block/slides, or frozen tissue) All-in-one test - Genome-wide HRD score by assessing loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST) - Genomic alterations in 437 cancer-relevant genes, including 26 HRR genes - Identifies numerous mutation types: single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions and large genomic rearrangements (LGR) - Assesses other key biomarkers: tumor mutation burden (TMB), microsatellite instability (MSI), DNA mismatch repair (MMR) genes, homologous recombination repair (HRR) genes GeneseeqPrime™HRD Report - 1 Evaluates HRD score and HRR-gene alterations to inform PARP inhibitor selection - 2 Assesses TMB, MSI and dMMR with the option to add the PD-L1 immunohistochemistry (IHC) test to better inform immunotherapy decisions - 3 Provides information on clinically actionable genomic alterations and their associated targeted therapy, both approved drugs and those in clinical trials - 4 Reveals potential resistance mechanisms to current therapies and options for alternative treatments